Immunitrack is specialized in next generation MHC-peptide technologies for best-in-class in vitro peptide immunogenicity assessment for optimized biologics, vaccines and immunotherapies. New ways of measuring and preparing MHC-peptide complex are provided to ensure cost-effective development of best-in-class biologic therapeutics.
Immunitrack was established in 2013, and its expertise has been validated through more than a decade of academic research. Companies that already benefit from Immunitrack’s platform technology include notable top 20 pharmaceutical and biotech companies